Neuromyelitis optica: a distinct demyelinating disease of the central nervous system
- 1 October 2008
- journal article
- review article
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 118 (4), 209-217
- https://doi.org/10.1111/j.1600-0404.2008.01002.x
Abstract
We review and discuss the pathogenesis, epidemiology, diagnosis as well as recent advances in the treatment of NMO. We also highlight areas of future research. A review was carried out on reports drawn from MEDLINE until 2007. Neuromyelitis optica (NMO) is a relative uncommon demyelinating disease of the central nervous system (CNS) that preferentially affects the optic nerves and spinal cord. NMO follows an unpredictable course, being either monophasic or relapsing. The relapsing form of NMO primarily affects women with onset varying from childhood to adults in their 40s or elderly. Until recently, NMO was considered to be a variant of multiple sclerosis. However, in contrast to multiple sclerosis, NMO attacks are not mediated by T cells but rather by B cells and NMO-immunoglobulin G antibodies that target aquaporin-4. Humoral immune mechanisms, including complement activation plays an important role in the pathogenesis of NMO. At present, parenteral corticosteroids are widely employed as first-line treatment of optic neuritis and myelitis attacks, whereas therapeutic plasmapheresis is applied in the case of corticosteroids failure. Various strategies for the prevention of NMO relapses have been employed in small case series with modest activity. Recent advances in the clinical, neuroimaging, laboratory and pathological hallmarks have established that NMO is a distinct demyelinating disease of the CNS.Keywords
This publication has 64 references indexed in Scilit:
- Nosology of idiopathic transverse myelitis syndromesActa Neurologica Scandinavica, 2007
- Neuromyelitis opticaCurrent Opinion in Neurology, 2007
- Relapsing neuromyelitis optica responsive to glatiramer acetate treatmentEuropean Journal of Neurology, 2007
- Pharmacokinetics of rituximab and its clinical use: Thought for the best use?Critical Reviews in Oncology/Hematology, 2007
- Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis OpticaPLoS Medicine, 2007
- Immunosuppressive therapy is more effective than interferon in neuromyelitis opticaMultiple Sclerosis Journal, 2007
- Acute longitudinal myelitis as the initial manifestation of Sjogren's syndromeJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosisBrain, 2005
- Idiopathic severe recurrent transverse myelitis: a restricted variant of neuromyelitis opticaClinical Neurology and Neurosurgery, 2005
- Mechanical ventilation and tracheostomy in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2004